The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.

Trace amine-associated receptor 1 (TAAR1) is a G protein-coupled receptor (GPCR) that is nonselectively activated by endogenous metabolites of amino acids. TAAR1 is considered a promising drug target for the treatment of psychiatric and neurodegenerative disorders. However, no selective ligand to identify TAAR1-specific signaling mechanisms is available yet. Here we report a selective TAAR1 antagonist, EPPTB, and characterize its physiological effects at dopamine (DA) neurons of the ventral tegmental area (VTA). We show that EPPTB prevents the reduction of the firing frequency of DA neurons induced by p-tyramine (p-tyr), a nonselective TAAR1 agonist. When applied alone, EPPTB increases the firing frequency of DA neurons, suggesting that TAAR1 either exhibits constitutive activity or is tonically activated by ambient levels of endogenous agonist(s). We further show that EPPTB blocks the TAAR1-mediated activation of an inwardly rectifying K(+) current. When applied alone, EPPTB induces an apparent inward current, suggesting the closure of tonically activated K(+) channels. Importantly, these EPPTB effects were absent in Taar1 knockout mice, ruling out off-target effects. We additionally found that both the acute application of EPPTB and the constitutive genetic lack of TAAR1 increase the potency of DA at D2 receptors in DA neurons. In summary, our data support that TAAR1 tonically activates inwardly rectifying K(+) channels, which reduces the basal firing frequency of DA neurons in the VTA. We hypothesize that the EPPTB-induced increase in the potency of DA at D2 receptors is part of a homeostatic feedback mechanism compensating for the lack of inhibitory TAAR1 tone.

Nitric oxide dependence of glutamate-mediated modulation at a vertebrate neuromuscular junction.

Recent evidence has revealed a contribution of glutamate in the stereotyped cholinergic neuromuscular transmission. Indeed, receptors, transporters and glutamate itself are present at the neuromuscular junction (NMJ) while glutamate activation of metabotropic receptors (mGluRs) decreases synaptic transmission and mediates depression through presynaptic mechanisms. However, we have shown that the mGluRs are located postsynaptically, inconsistent with the presynaptic action of glutamate. In the present study, we tested whether nitric oxide (NO) serves as a retrograde messenger mediating the distant effect of glutamate. Glutamate or an mGluR agonist [trans-(1S,3R)-aminocyclopentanedicarboxylic acid (ACPD)] failed to reduce synaptic transmission in the presence of an NOS inhibitor (3Br7NINa, 3-bromo-7-nitroindazole sodium salt). Moreover, application of 3Br7NINa precluded the effect of the mGluR antagonist MCPG [(S)-alpha-methyl-4-carboxyphenylglycine] on high-frequency-induced synaptic depression. Iontophoretic injections of BAPTA [1,2-bis(2-aminophenoxy)ethane-N,N,N'-tetraacetic acid] in muscle fibres abolished the effect of trans-ACPD on synaptic transmission and blocked the mGluR component of depression, indicating the involvement of muscular calcium in mGluR-induced depression. Also, the use of this protocol unveiled a muscular calcium-dependent potentiating pathway dependent on cyclo-oxygenase activity. In addition, local application of trans-ACPD induced an increase in NO production by muscle fibres visualized with the indicator DAF-FM (4-amino-5-methylamino-2',7'-difluorofluorescein). This was prevented by 3Br7NINa or the iontophoretic injection of BAPTA. Moreover, motor nerve stimulation (50 Hz, 30 s) induced an increase in DAF-FM fluorescence that was abolished by 3Br7NINa and MCPG. Hence, the data suggest that the production of the retrograde molecule NO depends on the postsynaptic calcium-dependent activation of nitric oxide synthase following mGluRs stimulation and is essential for the glutamatergic modulation of synaptic efficacy and plasticity at the NMJ.

GABAB receptors: physiological functions and mechanisms of diversity.

GABA(B) receptors are the G-protein-coupled receptors (GPCRs) for gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system. GABA(B) receptors are implicated in the etiology of a variety of psychiatric disorders and are considered attractive drug targets. With the cloning of GABA(B) receptor subunits 13 years ago, substantial progress was made in the understanding of the molecular structure, physiology, and pharmacology of these receptors. However, it remained puzzling that native studies demonstrated a heterogeneity of GABA(B) responses that contrasted with a very limited diversity of cloned GABA(B) receptor subunits. Until recently, the only firmly established molecular diversity consisted of two GABA(B1) subunit isoforms, GABA(B1a) and GABA(B1b), which assemble with GABA(B2) subunits to generate heterodimeric GABA(B(1a,2)) and GABA(B(1b,2)) receptors. Using genetic, ultrastructural, biochemical, and electrophysiological approaches, it has been possible to identify functional properties that segregate with these two receptors. Moreover, receptor modifications and factors that can alter the receptor response have been identified. Most importantly, recent data reveal the existence of a family of auxiliary GABA(B) receptor subunits that assemble as tetramers with the C-terminal domain of GABA(B2) subunits and drastically alter pharmacology and kinetics of the receptor response. The data are most consistent with native GABA(B) receptors minimally forming dimeric assemblies of units composed of GABA(B1), GABA(B2), and a tetramer of auxiliary subunits. This represents a substantial departure from current structural concepts for GPCRs.

Glutamatergic modulation of synaptic plasticity at a PNS vertebrate cholinergic synapse.

The presence and the functionality of a glutamatergic regulation was studied at the frog neuromuscular junction (NMJ), a singly innervated cholinergic synapse. Bath application of glutamate reduced transmitter release without affecting nerve-evoked presynaptic Ca2+ entry and handling. (1S,3R)-aminocyclopentanedicarboxylic acid (ACPD), a metabotropic glutamate receptor (mGluR) agonist, mimicked the effects of glutamate while (S)-alpha-methyl-4-carboxyphenylglycine (MCPG), a mGluR antagonist, blocked glutamate effects. MCPG had no effect on transmitter release evoked at low frequency (0.2 Hz) but significantly reduced synaptic depression (10 Hz, 80 s). This suggests that a frequency-dependent endogenous glutamatergic modulation is present at the frog NMJ and is mediated through mGluRs. Immunohistochemical labelling revealed the presence of mGluRs at the end plate area, primarily on muscle fibers. Functional glutamate uptake machinery was also found at the NMJ as blockade of glutamate transport by the inhibitor dl-threo-beta-benzyloxyaspartate (DL-TBOA) increased high frequency-induced depression, suggesting that the transporters system is used to eliminate glutamate from the extracellular space. Moreover, immunohistochemical labelling revealed that glutamate-aspartate transporters (GLASTs) are predominantly present on perisynaptic Schwann cells (PSCs). However, local application of glutamate on PSCs unreliability evoked small Ca2+ responses. Hence, these data suggest that functional glutamatergic interactions at a purely cholinergic synapse, shape synaptic efficacy and short-term plasticity in a frequency-dependent fashion.

Modulation of neurotransmission by reciprocal synapse-glial interactions at the neuromuscular junction.

Perisynaptic Schwann cells are glial cells that are closely associated with pre- and postsynaptic elements of the neuromuscular junction. Recent evidence shows that these cells detect and modulate neurotransmission in an activity-dependent fashion. Through G-protein signalling and Ca(2+) released from internal stores they can decrease or increase neurotransmitter release, respectively. Thus, they help to establish the level of neurotransmission associated with activity dependent short-term synaptic plasticity. We discuss evidence implicating perisynaptic Schwann cells as being active partners in neurotransmission at the neuromuscular junction, with emphasis on the modulation of short-term plasticity and potential implications for long-term changes.